Takara Bio USA, Inc., a pioneering life science reagent and instrument company and wholly owned subsidiary of Japan-based Takara Bio Inc., is partnering with BioExcel Diagnostics to develop and validate a new high-throughput and comprehensive method for detecting syndromic-based infectious diseases.

The method employs real-time PCR automation technology and reagents from Takara Bio to detect viruses, bacteria, fungi, and antimicrobial resistance genes specific to the contributing pathogen. Data generated allows clinicians to quickly determine the best route of treatment for their patients. 

BioExcel Diagnostics has developed and validated infectious disease panels to detect a unique combination of targets for common diseases. These infections include urinary tract infections, respiratory tract pathogens, sexually transmitted diseases, wound care, nail fungus, antibiotic resistance, and women’s health (coming soon).

Together with Takara Bio USA, BioExcel Diagnostics has adapted these panels for use on Takara Bio’s SmartChip Real-Time PCR System. Integration of the infectious disease panels with this multiplexed nanoscale qPCR technology will enable BioExcel Diagnostics to offer results from high-accuracy, advanced laboratory tests within 24–48 hours.